STOCKS TELEGRAPH

Tag: SXTC

  • China SXT Pharmaceuticals (SXTC) Surges After-Hours Amid Chinese Stock Rush

    China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) concluded Friday on a high note, climbing 6.5% to reach $1.15. However, the real excitement unfolded after hours, with SXTC experiencing a remarkable 22% surge, accompanied by a volume spike to nearly 2 million shares. This surge, twice the average volume, hints at significant market enthusiasm, especially from market bulls.

    After-Hours Momentum

    Despite the lack of immediate news driving this surge, investor optimism propelled the stock upwards. Many speculate a potential profit-taking downturn in the days ahead. Nevertheless, for now, bulls are relishing the ride.

    China SXT Pharmaceuticals, Inc. operates as a holding company specializing in the research, development, and distribution of traditional Chinese medicine pieces (TCMP), marketed under the Suxuantang brand. This surge aligns with the company’s strategic focus and market positioning. Notably, Chinese stocks like SXTC are favored during extended trading hours due to typically lower volumes, facilitating pump-and-dump strategies.

    Future Prospects and Financial Outlook

    The company’s unique business model involves offshore operations through subsidiaries and a consolidated variable interest entity in China. Despite past operating results, which may not fully reflect its current business lines, SXTC faces typical early-stage company challenges. These include attracting customers, managing costs, and navigating regulatory landscapes.

    While SXTC’s after-hours surge hints at continued momentum into the upcoming week, sustaining this trajectory hinges on trading volume. Investors should consider the broader market dynamics and the company’s ability to address evolving challenges and capitalize on growth opportunities.

    Conclusion

    In summary, China SXT Pharmaceuticals’ recent after-hours performance underscores market optimism but also highlights the need for caution amid potential profit-taking pressures and ongoing market volatility.

    Many in the market are keeping a close watch on this player, as well as other low-float, high potential China picks, that have the potential to take on a drastic rise during the extended hours.

  • China SXT Pharmaceuticals Inc. (SXTC) stock Under Corrections After Huge Gains

    The world’s oldest form of medicine, Traditional Chinese Medicine while still being considered unconventional, has been growing immensely lately. With acceptance even by Western doctors in renowned hospitals, the industry is continuing its expansion.

    One of the trending names in the industry was China SXT Pharmaceuticals Inc. (SXTC) on March 29, 2022. The traditional Chinese medicine pieces (TCMP) products company witnessed a huge uptick on Tuesday. The stock surged up in the regular session at a super active volume as investors seemed to be flocking towards it while there was no news from the company. Ultimately, the gain was followed by corrections in the after-hours, causing the stock to enter red in order to shed its gains. The latest news from the company date back to March 14 while the most recent SEC filing was on March 24.

    Source: Investment U

    During the regular trading session, SXTC increased by a huge 45.40% at a volume of 217.75 million shares. The stock closed the session at $0.2937 to plunge down to $0.2808 in the after hours. Hence, the stock lost 4.39% to corrections in the after hours.

    Why the Upsurge?

    Apparently, there is no company-specific news since the last securities purchase agreement was announced on March 14. Thus, the latest upsurge seems to be indicating investors’ interest in the stock due to external factors. While social media discussions are one aspect the stock’s low price might have been a reason as well. The interest in the stock seems to have been garnered while much is happening for the company and the wider industry alike. The company is currently working on regaining compliance with Nasdaq’s minimum bid requirement rule while Chinese and U.S. regulators are working towards the ongoing audit issues. Thus, China’s ban on foreign inspection of working papers from local accounting firms and the U.S.’ requirement of audit of Chinese audited forms for China-based companies finally seem to be moving towards a conclusion.

    SXTC Company Developments

    The company recently entered into a securities purchase agreement. The latest securities purchase agreement commenced on March 14 and closed on March 16, 2022. It included the issuance of a convertible promissory note in the original principal amount of $2,804,848.00 to Streeterville Capital, LLC.

    Furthermore, SXTC previously closed a $4.1 million follow-on underwritten offering along with the exercise of over-allotment on January 20. The offering equated to 22,777,774 of the company’s ordinary shares.

    Additionally, the company has until June 13, 2022, to regain compliance with Nasdaq’s minimum bid requirement of $1.00 or above.

  • China SXT Pharmaceuticals Inx. (SXTC) on a Bullish Roll Premarket. Here’s why?

    On March 18, China SXT Pharmaceuticals Inc. (SXTC) was trending in the premarket with a gain of 12.53% at the last check. With no official announcement from the company, the stock seems to be responding to external factors including market conditions.

    In the previous trading session on Thursday, the stock remained in the red with a loss of 6.06%. SXTC closed the session at $0.1980 while the volume of the shares traded was 7.36 million. In the premarket session today, the stock rebounded and was trading at a value of $0.2228 per share at the time of writing. The session’s volume was 354.2K shares at the time of writing.

    The holding company, China SXT Pharmaceuticals Inc. Deals in traditional Chinese medicines pieces (TCMP). Founded in 2005, the company has a market capitalization of $5.54 million with 17.85 million outstanding shares.

    What is Happening?

    SXTC stock had been in a downtrend well before the company announced a securities purchase agreement on March 14. The bearish trend in the stock seems to be related to the overall bearish momentum in Chinese stocks due to the Russia-Ukraine conflict. Most Chinese stocks have had a bearish sentiment for the past few weeks due to China’s relationship with Russia. It was only yesterday that reports emerged that the Chinese government has promised its support for economical stability. With a sigh of relief, most Chinese stocks recovered from their bearishness following the reports. Thus, SXTC also seems to have rebounded now that the market situation has improved. Moreover, the continuous downtrend was also expected to result in recovery due to corrections. Another reason that might have contributed is the closing of the offering announced on March 14.

    Source: Wise Geek

    As of now, SXTC seems to be enjoying gains as investors continue to buy its dip on market improvement.

    SXTC’s Securities Purchase Agreement

    On March 14, SXTC announced a securities purchase agreement for issuing a convertible promissory note in the original $2,804,848.0 to Streeterville Capital LLC. Streeterville is a limited liability company in Utah and the 12-month note has an annular interest rate of 6%.

    The offering was expected to close on March 16, 2022, and the company intends to use the net proceeds from it for general corporate purposes.

    SXTC’s Other Recent Developments

    On January 20, the company announced the closing of its underwritten public offering previously announced on January 14. The ordinary shares and pre-funded warrants’ offering closed simultaneously with the overallotment options for gross proceeds of $4.1 million.

  • China SXT Pharmacuticals Inc. (SXTC) Plunges Further on Underwritten Public Offering News

    China SXT Pharmacuticals Inc. (SXTC) Plunges Further on Underwritten Public Offering News

    On January 14, China SXTC Pharmacuticals Inc. (SXTC) announced a proposed underwritten public offering. Additionally, the company also announced details of its advanced TCMP products and the growth of Luxuejin. Consequent to the news, shares of SXTC plunged further in the pre-market on Tuesday.

    During regular trading, the stock fluctuated between $0.7899 and $0.4664 on Friday. SXTC closed the session at $0.5375 with a small loss of 0.44%. Following the announcement, the stock fell by a further 42.33% in the pre-market at $0.31.

    The traditional Chinese medicine holding company, China SXT Pharmacuticals Inc. has a market capitalization of $8.34 million. Currently, 15.53 million of the company shares are outstanding in the market.

    SXTC’s Public Offering

    As per Friday’s announcement, the company plans to offer its ordinary shares and pre-funded warrants for buying ordinary shares, in an underwritten public offering. Moreover, the per-share price of the pre-funded warrants will be the same as the ordinary shares, less $0.0001 per share exercise price of each pre-funded warrant. Furthermore, the base offering is expected to be up to $3.4 million approximately. Also, the company intends to award a 45-day overallotment option for buying 15% additional ordinary shares and/or pre-funded warrants.

    In addition, the size, actual terms, and completion date of the offering were not disclosed in the announcement.

    The sole book-running manager for the offering is Aegis Capital Corp.

    New Advanced TCMP Products

    As announced on Friday, the advanced TCMP products are Kuihuapan After-Soaking-Oral TCMP and Zhudanfen Directly-Oral TCMP products. Both the products are produced according to the processing specifications of Chinese Pharmacopoeia, 2020 Edition. The details of these products are as under:

    Kuihuapan Products

    Functions: clearing heat, calming the liver, dredging collaterals, and relieving pain.

    Indications: dizziness, tinnitus, joint pain, hyperuricemia, gout, hypertension, and other symptoms.

    Zhudanfen Products

    Functions:  clearing heat and moistening dryness, relieving cough and asthma, and detoxifying.

    Indications: sudden cough, asthma, fever, thirst, red eyes, throat obstruction, jaundice, diarrhea, dysentery, constipation, sores, carbuncle, swelling, and poison.

    SXTC expects the annual output of both these products to reach 300,000 bottles and sales of RMB 5M approx. during the year ending March 31, 2023.

    Luxuejin Updates

    Due to the GMP compliance inspection for SXTC’s new lyophilization production facilities in June 2021, the production cycle was delayed. Consequently, the production capacity also decreased. Following the completion of the inspection, the company had 12 batches of Luxuejin Directly-Oral TCMP products produced by lyophilization, as of December 31, 2021. The expected sales from this are over RMB 3M during the year ending on March 31, 2022.

  • China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    Shares of China SXT Pharmaceuticals, Inc. (SXTC) stock remained high in Monday’s pre-market trading session. SXTC stock was up by 33.33% to reach $2.44 a share at the time of this writing. It seems that SXTC stock was performing well in the previous trading session as it was up by 3.39% at the previous closing. But what made the stock high? Let’s deep dive to understand this bull.

    What’s happening?

    Sometimes nothing is good for everything and the same is the situation for SXTC stock. There is no particular activity by the China SXT stock, no press release today, no analysts’upgrades, or upswing targeted per share price of SXTC stock to support the rising stock price of China SXT. However it seems that sympathy play might be the driving force behind this bull as China Pharma Holdings, Inc has skyrocketed over 200% in pre-market session today in response to its fiscal year 2020 results.

    Recent Development

    Back on February 19, China SXT announced the approval of a 1 for 4 reverse split of its ordinary shares by its board of directors. These split-adjusted ordinary shares of SXTC began to trade on February 22, 2021. In connection with this announcement, shareholders of China SXT stock received one new share for every four shares which they owned. As of February 18, China SXT had approximately 62,057,584 outstanding ordinary shares which reduced to 15,514,396 approximately after the reverse split.

    Here is what you need to know about China SXT Pharmaceuticals, Inc.

    • China SXT is mainly operating in the fields of research, development, manufacturing, and marketing of its traditional Chine medicine piece tablets in the Republic of China. SXTC stock has a current market cap of 28.391M.
    • China SXT is a well-established company that provided services to 116 pharmaceutical companies, served 56 pharmacies and 76 hospitals as of May 2020.
    • Feng Zhou, a graduate of Pla National Defense University, is the Chief Executive Officer of the SXTC.
    • China SXT Pharmaceuticals was founded in 2005 and its headquarters are in Taizhou, China.

    Conclusion

    Things are going in favor of SXTC stock as far as market sentiment is concerned but no one knows how long this trend will continue in the future. There is no update about the earnings report so far by the China SXT. In a nutshell, investors should keep an eye on this stock.

  • Early Morning Vibes: 4 Stocks We Like for Monday…

    Early Morning Vibes: 4 Stocks We Like for Monday…

    The American stock markets could not be fired ahead last week. The results were limited and as you can see on the graph below, the S&P 500 continued to stabilize at around 3900 points. On Friday, the broad-based index closed 0.19% lower at 3,906 points and the Nasdaq was up 0.07% the day at 13,874 points.

    Investors are clearly waiting for new impulses but are also awaiting developments in the bond markets. Inflation expectations are increasing rapidly, and interest rates are also rising. The market now seems somewhat concerned that central banks will have to reduce the support measures or even raise interest rates sooner than expected. Finance minister Janet Yellen, however, said on Friday that governments must come up with a large package of support to revive economic growth.

    Currently, futures in New York are up to 1 percent lower. The European stock markets are also following the red figures. The decline again appears to be a direct result of rising interest rates. Furthermore, China yesterday asked the US to lift tariffs and other trade sanctions. China’s Foreign Minister continues to push for better US-China partnerships on technological progress. It remains to be seen how Joe Biden will react to the proposal, after his predecessor Trump just imposed strict measures.

    Meanwhile, Gold prices have been under pressure for several weeks, but on Friday even the support seemed to break at $ 1,764 (bottom November 30). However, the fear of rising interest rates is positive for gold and the price recovered. But watch out; higher interest rates are not good for gold, but the turmoil in the markets is. This morning, the gold price is at least 0.51% higher at $ 1792, but the danger is not over yet. The gold price is in a downward trend channel. A break above the last market stop at around $ 1,860 is necessary for technical improvement.

    Today Top Movers‎‎

    ‎Xcel Brands Inc. (XELB), an apparel manufacturing company, rose about 44.91% at ‎‎$2.92 in pre-market trading Monday.‎‎‎ ‎

    ‎China SXT Pharmaceuticals Inc. (SXTC) stock soared 280.89% to $2.99 in the pre-market trading. The company recently declared that a 1 for 4 reverse split of its ordinary shares was approved by the Company’s board of directors on January 23, 2021 and is expected to become effective on February 19, 2021.‎‎ ‎

    ‎ReTo Eco-Solutions Inc. (NASDAQ: RETO) shares are trading up 116.1% at $2.55 at the time of writing. ‎‎ ‎

    ‎RealNetworks Inc. (RNWK) grew over 12.68% at $4.0 in pre-market trading today.‎

    Top Upgrades & Downgrades

    KeyBanc turned bullish on AvalonBay Communities Inc. (AVB), upgrading the stock to “Overweight” and assigning a $200.0 price target, representing a potential downside of 12.25% from Friday’s close. 

    Marathon Petroleum Corporation (MPC) has won the favor of JPMorgan’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $67. 

    JetBlue Airways Corporation (JBLU) received an upgrade from analysts at Deutsche Bank, who also set their one-year price target on the stock to $21. They changed their rating on JBLU to Buy from Hold in a recently issued research note.

    Earlier Monday KeyBanc reduced its rating on Camden Property Trust (CPT) stock to Sector Weight from Overweight. 

    Kansas City Capital analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Valmont Industries Inc. (VMI) has been changed to Perform from Outperform. 

    Analysts at RBC Capital downgraded AngloGold Ashanti Limited (AU)’s stock to Sector Perform from Outperform Monday.

    Latest Insider Activity

    Palantir Technologies Inc. (PLTR) Director THIEL PETER announced the sale of shares taking place on Feb 18 at $25.23 for some 20,003,915 shares. The total came to more than $504.78 million. 

    Tesla Inc. (TSLA) Chief Financial Officer Kirkhorn Zachary sold on Feb 17 a total of 55,007 shares at $778.17 on average. The insider’s sale generated proceeds of almost $0.97 million. 

    Onconova Therapeutics Inc. (ONTX) SVP Corp Dev & Gen Counsel OLER ABRAHAM N. declared the purchase of shares taking place on Feb 16 at $1.00 for some 12,000 shares. The transaction amount was around $12000.0. 

    JMP Group LLC (JMP) Possible Member of 10% Group WEDBUSH SECURITIES INC bought on Feb 11 a total of 2,019,000 shares at $4.74 on average. The purchase cost the insider an estimated $920.

    Important Earnings

    Top US earnings releases scheduled for today include Marathon Oil Corporation (NYSE: MRO). It will announce its Dec 2020 financial results. The company is expected to report earnings of -$0.2 per share from revenues of $838.05M in the three-month period. 

    Analysts expect Occidental Petroleum Corporation (NYSE: OXY) to report a net income (adjusted) of -$0.59 per share when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $4.37B. 

    Invesco Mortgage Capital Inc. (IVR), due to announce earnings after the market closes today, is expected to report earnings of $0.06 per share from revenues of $29.16M recently concluded three-month period.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.

  • Top 15 Healthcare Stocks You Should Add To Your Bucket

    The global generics drug market continues to grow with the increasing demand for more medication. Drug manufacturers are continuously striving to meet the need for more generic drugs. This industry is an opportunity-rich industry. Efficient and inexpensive drugs are often needed. The drug manufacturing industry has seen a huge transformation over the last two decades.

    This industry-main challenge is to provide the drug at lower prices than branded drugs. Drug manufacturers and Specialty Generic Industry will face more pressure in the coming years to lower the prices of drugs.  The industry is expected to grow significantly over the next decade. Check out the leading companies in drug manufacturers- specialty generic industry to see how these are addressing the needs of their customers:

    Sundial Growers Inc. (NASDAQ: SNDL)

    Sundial Growers Inc. (NASDAQ: SNDL) shares were trading down -6.32% at $0.17 at the time of writing on Wednesday. Sundial Growers Inc. (NASDAQ: SNDL) share price went from a low point around $0.17 to briefly over $4.12 in the past 52 weeks, though shares have since pulled back to $0.17. SNDL market cap has remained high, hitting $32.59M at the time of writing, giving it a price-to-sales ratio of more than 0.

    Sundial Growers Inc. (SNDL) has revealed earlier that it has expanded the Palmetto brand presence across Canada. If we look at the recent analyst rating SNDL, CIBC upgraded coverage on SNDL shares with a Neutral rating.

    Teligent Inc. (NASDAQ: TLGT)

    Teligent Inc. (NASDAQ: TLGT) last closed at $1.04, in a 52-week range of $0.65 to $8.00. The Schall Law Firm has earlier revealed that it is investigating claims on behalf of investors in Teligent, Inc. for potential breaches of fiduciary duty on the part of its directors and management. Teligent Inc.’s market cap has remained high, hitting $5.68 Million at the time of writing.

    Zomedica Corp. (AMEX: ZOM)

    Zomedica Corp. (AMEX: ZOM) stock drop by -3.82% to $0.08. Zomedica Corp. (ZOM) revealed that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will start trading under the new name effective on October 5, 2020.

    Aurora Cannabis Inc. (NYSE: ACB)

    Aurora Cannabis Inc. (NYSE: ACB) shares headed rising, higher as much as 6.36%. The most recent rating by Jefferies, on September 21, 2020, is at a Hold. Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of Aurora Cannabis Inc. (ACB) shareholders.

    Tilray Inc. (NASDAQ: TLRY)

    Tilray Inc. (NASDAQ: TLRY) rose 2.96% after gaining more than $0.19 on Wednesday. Tilray Inc. (TLRY) earlier revealed that its wholly-owned subsidiary, High Park Holdings Ltd. has introduced the newest addition to its cannabis-infused edible product line: Chowie Wowie Gummies, which are now available in select provinces across Canada.

    Neos Therapeutics Inc. (NASDAQ: NEOS)

    Neos Therapeutics Inc. (NASDAQ: NEOS) last closed at $0.86, in a 52-week range of $0.45 to $1.98. Neos Therapeutics Inc. (NEOS) has reported that its sales in quarter two reached $13.13 million. However, earnings dropped by 51.17%, resulting in a loss of $2.88 million. In Q1, Neos Therapeutics brought in $14.49 million in sales but lost $5.89 million in earnings.

    Teva Pharmaceutical Industries Limited (NYSE: TEVA)

    Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares headed rising, higher as much as 3.72%. The most recent rating by Barclays, on August 06, 2020, is at an Equal-weight. Pomerantz LLP revealed that a class action lawsuit has been lodged against Teva Pharmaceuticals Industries Limited and certain of its officers.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) shares headed falling, lower as much as -2.56%. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Overweight. Elanco Animal Health Incorporated (ELAN) has revealed that it has got a notification of an unsolicited ‘mini-tender”‘ offer by TRC Capital Investment Corporation to buy up to 4,000,000 shares of Elanco common stock, representing approximately 1.00% of the outstanding shares of Elanco common stock.

    HEXO Corp. (NYSE: HEXO)

    HEXO Corp. (NYSE: HEXO) fall -0.91% after losing more than -$0.01 on Wednesday. HEXO Corp. (HEXO) has earlier disclosed that it has appointed Trent MacDonald to its executive leadership team in the acting role of Chief Financial Officer, effective October 10, 2020. Its market cap has remained high, hitting $365.78 million at the time of writing.

    Bausch Health Companies Inc. (NYSE: BHC)

    Bausch Health Companies Inc. (BHC) last closed at $17.57, in a 52-week range of $11.15 to $31.97. Analysts have a consensus price target of $26.76. Bausch Health Companies Inc. (BHC) and Lomb, its leading global eye health business, along with BHVI, revealed previously that an affiliate of Bausch Health has bought an exclusive license for a myopia control contact lens design developed by BHVI.

    Endo International plc (NASDAQ: ENDP)

    Endo International plc (NASDAQ: ENDP) stock drop by -5.69% to $5.47. The most recent rating by Goldman, on July 27, 2020, is at a Sell. Endo International plc (ENDP) revealed that it has decided to buy all of the outstanding shares of BioSpecifics Technologies Corp. for $88.50 in cash per share or an estimated enterprise value of approximately $540 million at the expected time of deal closure.

    China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

    China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) stock soar by 9.65% to $0.31. China SXT Pharmaceuticals Inc. (SXTC) share has fluctuated between the 52-weeks low of $0.22 and 52-weeks high of $1.56 during the trading session of Wednesday. It has moved up 40.64% from its 52-weeks low and moved down -79.97% from its 52-weeks high.

    Canopy Growth Corporation (NYSE: CGC)

    Canopy Growth Corporation (NYSE: CGC) rose 3.23% after gaining more than $0.61 on Wednesday. Canopy Growth Corporation (CGC) share price went from a low point around $9.00 to briefly over $25.97 in the past 52 weeks, though shares have since pulled back to $19.49. CGC market cap has remained high, hitting $7.24 billion at the time of writing.

    Aphria Inc. (NASDAQ: APHA)

    Aphria Inc. (NASDAQ: APHA) last closed at $4.68, in a 52-week range of $1.95 to $6.44. Aphria Inc. (APHA) has moved up 140.00% from its 52-weeks low and moved down -27.33% from its 52-weeks high. Its market cap has remained high, hitting $1.25 billion at the time of writing.

    China Pharma Holdings Inc. (CPHI)

    China Pharma Holdings Inc. (CPHI) stock soar by 6.86% to $0.50. The most recent rating by Rodman & Renshaw, on January 08, 2010, is at an Mkt outperform. China Pharma Holdings Inc. (CPHI) has moved up 134.13% from its 52-weeks low and moved down -64.53% from its 52-weeks high. Its market cap has remained high, hitting $22.72 million at the time of writing.